Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C26H28N3.C23H16O6 |
Molecular Weight | 1153.4108 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 2 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC2=C(C=C1)[N+](C)=C(\C=C\C3=C(C)N(C(C)=C3)C4=CC=CC=C4)C=C2.CN(C)C5=CC6=C(C=C5)[N+](C)=C(\C=C\C7=C(C)N(C(C)=C7)C8=CC=CC=C8)C=C6.OC(=O)C9=CC%10=C(C=CC=C%10)C(CC%11=C%12C=CC=CC%12=CC(C(O)=O)=C%11O)=C9O
InChI
InChIKey=OOPDAHSJBRZRPH-UHFFFAOYSA-N
InChI=1S/2C26H28N3.C23H16O6/c2*1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h2*6-18H,1-5H3;1-10,24-25H,11H2,(H,26,27)(H,28,29)/q2*+1;
Pyrvinium (Viprynium) is an anthelmintic effective for pinworms. Pyrvinium is used in the treatment of enterobiasis caused by Enterobius vermicularis (pinworm). Pyrvinium has being shown to be a potent inhibitor of Wnt signaling (EC(50) of ∼10 nM). Pyrvinium binds all casein kinase 1 (CK1) family members in vitro at low nanomolar concentrations and pyrvinium selectively potentiates casein kinase 1α (CK1α) kinase activity. Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). A noncompetitive AR inhibitor pyrvinium has significant potential to treat CRPC, including cancers driven by ligand-independent AR signaling.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2793 |
|||
Target ID: CHEMBL612855 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18591280 |
354.0 nM [IC50] | ||
Target ID: CHEMBL1871 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Curative | POVAN Approved UsePyrvinium is used to treat pinworms (enterobiasis). |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1269218
single 350-mg dose
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25060218
Pyrvinium blocked colon cancer cell growth in vitro in a dose-dependent manner with great differences in the inhibitory concentration (IC(50)), ranging from 0.6 × 10(-6) to 65 × 10(-6) mol/L for colon cancer cells with mutations in WNT signaling.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
46174068
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
1592001
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
m9406
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | Merck Index | ||
|
C024631
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
C66499
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
223622
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
310X6S84LW
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
222-596-3
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
DTXSID4023545
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
55347
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT001378
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
3546-41-6
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
100000089904
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201303
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY | |||
|
SUB04154MIG
Created by
admin on Fri Dec 15 14:58:14 GMT 2023 , Edited by admin on Fri Dec 15 14:58:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD